Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …

Gastroesophageal cancer dynamics and drivers of clinical responses with immune
checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual …

A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the
potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the …

Gastric cancers, with gastric adenocarcinoma (GAC) as the most common histological type,
impose a considerable global health burden. Although the screening strategies for early …

Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to
a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD …

The success of checkpoint inhibitors in cancer treatment is associated with the infiltration of
tissue-resident memory T (Trm) cells. In this study, we found that about 30% of tumor …

The T-cell surface molecule TIGIT is an immune checkpoint molecule that inhibits T-cell
responses, but its roles in cancer are little understood. In this study, we evaluated the role …

Gastric cancer is one of the most aggressive malignancies, with limited treatment options in
both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic …